Literature DB >> 2310345

Vitreous cefazolin levels after intravenous injection. Effects of inflammation, repeated antibiotic doses, and surgery.

D F Martin1, L A Ficker, H A Aguilar, S K Gardner, L A Wilson, T A Meredith.   

Abstract

We devised a standardized rabbit model of intraocular inflammation using heat-killed Staphylococcus epidermidis as the inducing organism. We applied this model to study the effects of (1) inflammation, (2) repeated antibiotic doses, and (3) surgical status of the eye on cefazolin levels in the vitreous cavity after intravenous administration. Intravenous cefazolin sodium, 50 mg/kg, was administered every 8 hours for 48 hours. Eyes were harvested for assay of vitreous cavity antibiotic levels at various intervals from 1 to 49 hours. Drug levels were compared in inflamed and noninflamed eyes under both phakic and aphakic/vitrectomized conditions. At 1 hour, levels in phakic specimens were 3.0 mg/L in inflamed eyes vs undetectable in noninflamed eyes (P less than .01), but progressively increased to 10.6 mg/L at 49 hours (P less than .02) in inflamed eyes only. Levels in aphakic/vitrectomized eyes at 1 hour were 6.7 mg/L in inflamed eyes vs 4.2 mg/L in noninflamed eyes (P less than .1), but progressively increased to 24.9 mg/L at 49 hours (P less than .001) in inflamed eyes only. Levels at 49 hours in inflamed phakic and inflamed aphakic/vitrectomized eyes were well above the minimum inhibitory concentrations for organisms termed sensitive to cefazolin. We would conclude, therefore, that repeated doses of intravenous cefazolin may play an important adjunctive role in the treatment of endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2310345     DOI: 10.1001/archopht.1990.01070050109043

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  14 in total

1.  Vitreous replacement by gas as a therapeutic modality in bacterial endophthalmitis.

Authors:  A M Mansour; E Ferguson; H Lucia; M Rajashekhar; H Li; T Margo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

2.  Repeated IL-10 measurement in aqueous humor and OCT imaging are valuable tools to monitor intraocular lymphoma treated with intravitreal injections of methotrexate.

Authors:  Maher Saleh; Katerina Nikolitch; Tristan Bourcier; Claude Speeg; David Gaucher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-07-15       Impact factor: 3.117

3.  Passage of drugs through different intraocular microdialysis membranes.

Authors:  J Waga; B Ehinger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-01       Impact factor: 3.117

4.  Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.

Authors:  Seenu M Hariprasad; William E Mieler; Gaurav K Shah; Kevin J Blinder; Rajendra S Apte; Nancy M Holekamp; Matthew A Thomas; Jingduan Chi; Randall A Prince
Journal:  Trans Am Ophthalmol Soc       Date:  2004

5.  Intravenous cefazolin in penetrating eye injuries. I. Effects of trauma and multiple doses on intraocular delivery.

Authors:  D V Alfaro; P E Liggett
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-04       Impact factor: 3.117

6.  Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials.

Authors:  W Liu; Q F Liu; R Perkins; G Drusano; A Louie; A Madu; U Mian; M Mayers; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  Antimicrobial pharmacokinetics in endophthalmitis treatment: studies of ceftazidime.

Authors:  T A Meredith
Journal:  Trans Am Ophthalmol Soc       Date:  1993

8.  Vitreous penetration of orally administered gatifloxacin in humans.

Authors:  Seenu M Hariprasad; William F Mieler; Eric R Holz
Journal:  Trans Am Ophthalmol Soc       Date:  2002

9.  Effect of inflammation on intraocular penetration of intravenous ofloxacin in albino rabbits.

Authors:  G Gatti; G Panozzo
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

10.  Evolution of Intravitreal Therapy for Retinal Diseases-From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture.

Authors:  Daniel F Martin
Journal:  Am J Ophthalmol       Date:  2018-01-12       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.